E2F-1 is a critical modulator of cellular senescence in human cancer

Int J Mol Med. 2006 May;17(5):715-20.

Abstract

Senescence limits cellular proliferation, and therefore might be a mechanism which could suppress the progression of cancer. Herein we show that E2F1, a transcription factor essential to a cell cycle progress and a main target of tumor suppressor Rb, is a critical barrier for the induction of senescence. Human cancer cells transfected with siE2F1 were shown to express replicative senescence markers, in addition to yielding positive results upon SA-beta-Gal staining. Consistent with the notion of the critical role in senescence of E2F1, cells which overexpressed E2F1 proved to be immune to the induction of senescence. Importantly, it appears that E2F1 depletion-induced cancer cell senescence is not reliant on the integrity of either Rb or p53. Our results provide a molecular explanation for the selectivity with which senescence induction occurs, and also provides insights into the possibility of using E2F1 as a therapeutic target in the treatment of cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology
  • Blotting, Western
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cellular Senescence / drug effects
  • Cellular Senescence / genetics
  • Cellular Senescence / physiology*
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • Cyclin-Dependent Kinase Inhibitor p27 / metabolism
  • Doxorubicin / pharmacology
  • E2F1 Transcription Factor / genetics
  • E2F1 Transcription Factor / metabolism
  • E2F1 Transcription Factor / physiology*
  • Humans
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Neoplasms / physiopathology
  • Retinoblastoma Protein / metabolism
  • Time Factors
  • Transfection
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Antibiotics, Antineoplastic
  • Cyclin-Dependent Kinase Inhibitor p21
  • E2F1 Transcription Factor
  • Retinoblastoma Protein
  • Tumor Suppressor Protein p53
  • Cyclin-Dependent Kinase Inhibitor p27
  • Doxorubicin